Treatment modification patterns of glucose-lowering agents in Saudi Arabia: A retrospective real-world data analysis
Authors' conclusion
Nearly half of patients experienced modifications or interruptions, with notable shifts between monotherapies and dual therapies. These findings highlight the evolving landscape of treatment patterns in Saudi Arabia and guide future research and decision-making.
Study context
- Population
- Saudi patients ≥18 years with at least one antidiabetic prescription between 2016 and 2022
- Participants
- 122,291 patients
- Outcome
- Antidiabetic modification patterns: add-on (new antidiabetic within a treatment episode) and switching (new treatment episode after the preceding ends)
Methodological detailsreal-world data, descriptive
- Real-world data
- Descriptive
Main finding
As reported in the abstract
Treatment interruption or modification
- Patients with treatment interruption or modification
- 47.2 %
- Total events
- 303,781
- Interruptions, share of events
- 54 %
- Add-on, share of events
- 11 %
- Switching, share of events
- 35 %
- Median time to first event
- 159 days
Observational data: associations, not effects.
Further findings
Most common add-on
%
- DPP-4i added to biguanide and SU
- 8
- SU added to biguanide
- 8
Switching patterns (106,405 switching events)
%
- Dual therapy to monotherapy
- 23
- Monotherapy to dual therapy
- 17
Original publication
Treatment modification patterns of glucose-lowering agents in Saudi Arabia: A retrospective real-world data analysis. Diabetes Res Clin Pract. Published 4 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →